Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.

In the following series of videos, faculty discuss therapeutic options for triple-negative breast cancer. Topics discussed include the biology of triple-negative breast cancer, current treatment options, novel targeted treatments, PARP inhibitors, and immunotherapy.

In the following series of videos, faculty discuss therapeutic options for triple-negative breast cancer. Topics discussed include the biology of triple-negative breast cancer, current treatment options, novel targeted treatments, PARP inhibitors, and immunotherapy.

In the following series of videos, faculty discuss therapeutic options for triple-negative breast cancer. Topics discussed include the biology of triple-negative breast cancer, current treatment options, novel targeted treatments, PARP inhibitors, and immunotherapy.

In the following series of videos, faculty discuss therapeutic options for triple-negative breast cancer. Topics discussed include the biology of triple-negative breast cancer, current treatment options, novel targeted treatments, PARP inhibitors, and immunotherapy.

In the following series of videos, faculty discuss therapeutic options for triple-negative breast cancer. Topics discussed include the biology of triple-negative breast cancer, current treatment options, novel targeted treatments, PARP inhibitors, and immunotherapy.

Published April 18, 2012 | By Dr Quesnelle | 7 Comments
From the Grace Archives | Originally Published April 6, 2012 | By Dr West
From the Grace Archives | Originally Published April 20, 2012 | By Dr. Cianfrocca
It’s a very enticing proposition….that a single, over the counter pill can reduce the risk of heart attack and stroke as well as cancer. Are we there yet? Should we be recommending routine aspirin use even in people without significant cardiovascular risk factors?
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.